BSECompany Update13 Aug 2026 · 13 Aug 2026, 11:56 am

Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

Alivus Life Sciences Ltd · 543322

✦ AI SummaryMgmt Change

Alivus Life Sciences Ltd has announced an investors/analyst meeting on August 18-19, 2026, with various investment firms, including Green Lantern Capital, SIMPL, Burman Capital, and Karma Capital.

Analysis Scores

Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Alivus Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Attachments (1)

📄

c8e7d953-9d5f-4441-be71-fe854ba66b15.pdf

pdf

Download →
View document text
August 13, 2026 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 – Intimation of Investors/Analyst Meetings With reference to the captioned subject and pursuant to Regulation 30 and Para A of Part A of Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform the details of Investors/Analyst meetings to be conducted as follows: Date Name Mode Place Type of Meeting August 18, 2026 Green Lantern Capital In-Person Mumbai One on One August 18, 2026 SIMPL In-Person Mumbai One on One August 19, 2026 Burman Capital Virtual - One on One August 19, 2026 Karma Capital In-Person Mumbai One on One The schedule and mode of meeting may undergo a change due to exigencies on part of the Investor/Analyst/Company. You are requested to kindly takes note of the same. Thanking You, Your Sincerely, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Corporate Office: Registered Office: Technopolis Knowledge Park, A wing, Office No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri ( E), Mumbai – 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com